Abstract
Rhinovirus is the most common trigger for asthma exacerbations and causes neutrophilic inflammation. Neutrophilic inflammation and airway mucus in asthma exacerbations are often resistant to effects of glucocorticoids, and there are no specific therapies. Anakinra (IL-1 receptor antagonist) treatment reduces inhaled LPS-induced inflammation in humans. We hypothesize that anakinra treatment will reduce rhinovirus-mediated pro-inflammatory cytokine production from the airway epithelium important for neutrophil recruitment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
